Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s
Digest more
The Financial Express on MSN
Novo Nordisk stock plunges to a four-year-low. Here is the reason behind the slump
Novo Nordisk shares plunge after semaglutide Alzheimer’s trial fails to meet its main goal, deepening pressure amid ...
Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...
A new study reported that Novo Nordisk spent $7.5 million over 2 years on more than 15,000 internet keywords — many focused ...
Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...
By Jacob Gronholt-Pedersen COPENHAGEN (Reuters) -Four patients in Denmark, who experienced vision loss after using Novo ...
Novo Nordisk cuts Wegovy's price and commits fully to its upcoming weight-loss pill to stay competitive in the fast-growing ...
Four patients who developed a serious eye disease after using Novo Nordisk A/S’s blockbuster weight-loss drugs have been granted compensation in Denmark, the drugmaker’s home market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback